Back to Journals » Cancer Management and Research » Volume 11

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Authors Remon J, Esteller L, Taus Á

Received 26 February 2019

Accepted for publication 24 April 2019

Published 29 May 2019 Volume 2019:11 Pages 4893—4904

DOI https://doi.org/10.2147/CMAR.S164935

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Antonella D'Anneo


Jordi Remon,1 Laura Esteller,1 Álvaro Taus2,3

1Centro Integral Oncología Clara Campal Barcelona, HM-Delfos, Medical Oncology Department, Barcelona, Spain; 2Hospital del Mar, Medical Oncology Department, Barcelona, Spain; 3Oncology Department, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Abstract: Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in combination with chemotherapy have become the standard of care in the first-line treatment strategy of advanced non-small cell lung cancer (NSCLC) patients. Combination treatment with ICI, such as nivolumab and ipilimumab or durvaluamb and ipilimumab, has also been proposed as potential strategies in this setting in selected advanced NSCLC patients. Characterizing predictive markers of long-term clinical benefit with ICI is a critical objective. Tumor mutational burden has been proposed as a potential predictive biomarker. In this review, we discuss the efficacy of nivolumab and ipilimumab in advanced NSCLC patients as well as the clinical utility of tumor mutational burden in the efficacy of this combination. Ongoing clinical trials with nivolumab and ipilimumab, and the efficacy of this combination in subgroups of NSCLC patients, such as elderly patients and patients with brain metastases, are also discussed.

Keywords: nivolumab, ipilimumab, tumor mutational burden, CheckMate trial, non-small cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]